We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




N-acetylcysteine Protects Dopamine-Producing Neurons from Stress Damage and Eases Parkinson's Symptoms

By LabMedica International staff writers
Posted on 27 Jun 2016
A preliminary clinical study demonstrated the effectiveness of n-acetylcysteine (NAC) in promoting survival of neurons and alleviating symptoms in patients with Parkinson's disease (PD).

Previous studies have shown that oxidative stress in the brain may play an important role in the Parkinson's disease process, and that this stress reduces levels of the antioxidant glutathione. More...
NAC acts to reduce oxidative damage to neurons by restoring glutathione levels.

The purpose of the clinical study carried out by investigators from Thomas Jefferson University (Philadelphia, PA, USA) was to explore the effects of NAC using both an in vitro and in vivo approach. To find supportive data for the pilot clinical study, the investigators performed a cell line tissue culture study in which they used a model of PD that employed midbrain dopamine (mDA) neurons generated from human embryonic stem cells (hESCs) to determine whether NAC could protect these mDA neurons from damage resulting from exposure to increasing doses of the PD-like neurotoxin, rotenone.

In the clinical study, patients continued their standard of care and were randomized to receive either daily NAC, alternating between oral and IV administration, or no NAC. Patients were evaluated before and after three months of receiving NAC with DaTscan to measure dopamine transporter (DAT) binding and the Unified Parkinson’s Disease Rating Scale (UPDRS) to measure clinical symptoms.

Results published in the June 16, 2016, online edition of the journal PLOS One revealed that in the cell line study NAC exposure resulted in significantly more mDA neurons surviving after exposure to rotenone compared to no NAC, consistent with the protective effects of NAC previously observed. In the clinical trial the patients receiving NAC had improvements of 4-9% in dopamine transporter binding and about a 13% improvement in their UPDRS score as compared to untreated control patients.

"This study reveals a potentially new avenue for managing Parkinson's patients and shows that n-acetylcysteine may have a unique physiological effect that alters the disease process and enables dopamine neurons to recover some function," said senior author Dr. Daniel Monti, professor of integrative medicine at Thomas Jefferson University.

Related Links:
Thomas Jefferson University



Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
High-Density Lipoprotein Containing Cholesterol Assay
HDL-c direct FS
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.